Table 4.
Change in parameters between baseline and 6-months follow-up. Change in parameters that are associated with JIA (paediatric rheumatologist) and uveitis (ophthalmologist) and patient reported outcome measures from baseline to 6-months follow-up (bold highlighted beta/ OR were statistically significant)
| Baseline | 3-months follow-up | 6-months follow-up | Change between Baseline and 3-months follow-up | Change between Baseline and 6-months follow-up | Change between 3-months and 6-months follow-up | Effect Size Baseline to 6-months follow-up |
|
|---|---|---|---|---|---|---|---|
| n; mean (sd), median | n; mean (sd), median | n; mean (sd), median | beta/ OR p value 95% CI | beta/ OR p value 95% CI | beta/ OR p value 95% CI | ||
| n(%)a | n(%)a | n(%)a | |||||
| Analyses on patient level | |||||||
| n = 82 | n = 77 | n = 64 | |||||
| Pediatric rheumatologist | |||||||
| Physician’s global about JIA disease activity, VAS, 0–100 | 71; 34.0 (28.7); 30 | 64; 17.0 (22.6); 10 | 57; 13.4 (22.4); 5 | −17.7 < 0.001–23.29; −12.14 | −20.2 < 0.001–26.09; −14.41 | −2.5 0.401–8.46; 3.38 | 0.66 |
| Number of joints with active arthritis | 83; 0.6 (1.5); 0 | 77; 0.4 (1.5); 0 | 64; 0.9 (3.8); 0 | −0.1 0.636–0.77; 0.47 | 0.3 0.313–0.32; 1.00 | 0.5 0.152–0.18; 1.15 | 0.10 |
| Patients reported outcomes | |||||||
| Overall well-being; VAS; 0–100 | 47; 34.1 (29.7); 26 | 43; 23.5 (20.3); 20 | 30; 23.2 (22.3); 12 | −10.5 0.003–17.48; −3.62 | −13.1 0.001–20.93; −5.27 | − 2.6 0.524–10.39; 5.29 | 0.41 |
| C-HAQ, 0–3 | 35; 0.81 (1.04); 0.5 | 27; 0.69 (0.88); 0.5 | 18; 0.52 (0.59); 0.44 | − 0.2 0.056–0.45; 0.01 | − 0.3 0.014–0.61; − 0.07 | −0.1 0.4–0.39; 0.16 | 0.13 |
| PedsQL, 0–100 | 52; 78.7 (21.5); 87.8 | 40; 81.7 (17.9); 86.9 | 26; 85.5 (13.5); 89.7 | 3.8 0.088–0.57; 8.21 | 7.2 0.006 2.08; 12.30 | 3.4 0.201–1.80; 8.54 | 0.15 |
| Number of days in hospital due to uveitis | 40; 1.9 (6.0); 0 | 32; 0.7 (2.7); 0 | 19; 1.1 (4.2); 0 | −1.2 0.274–3.33; 0.94 | −0.7 0.561–3.26; 1.77 | 0.4 0.736–2.16; 3.06 | 0.25 |
| Missed days in kindergarden/ school due to uveitis | 51; 4.8 (6.7); 1 | 47; 3.2 (9.2); 0 | 32; 0.5 (1.6); 0 | −1.7 0.211–4.30; 0.95 | −4.3 0.004–7.25; − 1.34 | −2.6 0.085–5.61; 0.37 | 0.20 |
| Number of days with restrictions in daily life due to uveitis | 39; 7.4 (16.9); 0 | 32; 1.7 (4.8); 0 | 19; 5.0 (10.6); 0 | −5.9 0.037–11.40; − 0.36 | −2.7 0.417–9.25; 3.83 | 3.2 0.355–3.55; 9.90 | 0.44 |
| Analyses on eye level | |||||||
| n = 147 | n = 132 | n = 103 | |||||
| Ophthalmologist | |||||||
| Physician’s global about disease activity in the eyes, VAS, 0–100 | 113; 45.2 (33.9); 50 | 111; 30.6 (33.5); 20 | 87; 25.2 (32.3); 14 | −15.0 < 0.001–19.13; − 10.83 | −20.0 < 0.001–24.57; − 15.44 | − 5.0 0.029–9.55; − 0.51 | 0.43 |
| Total number of AC cells | 46; 7.4 (6.4); 7.5 | 28; 1.4 (3.2); 0 | 33; 1.9 (4.8); 0 | −4.9 < 0.001–6.99; − 2.79 | − 5.0 < 0.001–7.03; − 2.91 | −0.1 0.942–2.29; 2.12 | 1.10 |
| Visual acuity, logMAR | 119; 0.48 (0.51); 0.3 | 101; 0.39 (0.50); 0.1 | 86; 0.42 (0.52); 0.11 | −0.1 0.015–0.11; − 0.01 | −0.1 0.062–0.10; 0.00 | 0.0 0.727–0.04; 0.06 | 0.18 |
| AC cell grade | 136; 2.81 (1.25); 3 | 116; 1.81 (1.20); 1 | 93; 1.39 (0.82); 1 | −1.0 < 0.001–1.26; − 0.80 | −1.5 < 0.001–1.72; − 1.22 | −0.4 0.001–0.69; − 0.19 | 0.81 |
| AC flare grade (no flare versus flare), SUN | 99 (70.2%) | 49 (38.6%) | 24 (25.3%) | 0.1 < 0.001 0.03; 0.21 | 0.0 < 0.001 0.01; 0.08 | 0.3 0.006 0.12; 0.71 | 0.67 |
| AC flare grade (no flare versus flare), MIWGUC | 53 (61.6%) | 31 (37.4%) | 17 (25.8%) | 0.1 < 0.001 0.03; 0.34 | 0.0 < 0.001 0.01; 0.14 | 0.3 0.032 0.09; 0.90 | 0.50 |
| Any structural complications | 81 (56.3%) | 73 (56.2%) | 64 (62.1%) | 0.9 0.867 0.27; 2.99 | 1.1 0.904 0.28; 4.28 | 1.2 0.79 0.30; 4.77 | 0.01 |
| Ocular hypotony | 3 (2.1%) | 3 (2.4%) | 0 (0.0%) | b | b | b | 0.02 |
| Ocular hypertension | 6 (4.3%) | 8 (6.5%) | 4 (4.1%) | 6.2 0.235 0.31; 124.32 | 0.2 0.321 0.01; 4.05 | 0.0 0.109 0.00; 2.06 | 0.09 |
| Posterior synechiae | 60 (43.2%) | 60 (46.2%) | 53 (52.0%) | 5.7 0.23 0.33; 96.67 | 4.7 0.324 0.21; 104.42 | 0.8 0.903 0.05; 15.33 | 0.06 |
| Glaucoma | 6 (4.4%) | 6 (5.1%) | 5 (5.4%) | b | b | b | 0.03 |
| Cataract | 28 (19.9%) | 23 (18.3%) | 24 (23.5%) | b | b | b | 0.04 |
| Band keratopathy | 31 (21.5%) | 31 (24.6%) | 27 (26.7%) | 25.6 0.067 0.80; 826.75 | 14.8 0.132 0.44; 493.90 | 0.6 0.716 0.03; 11.13 | 0.07 |
| Optic disc edema | 10 (10.9%) | 6 (7.0%) | 3 (4.8%) | b | b | b | 0.11 |
| Macular edema (Funduscopy) | 9 (7.0%) | 4 (5.0%) | 2 (2.9%) | 0.3 0.288 0.04; 2.68 | 0.2 0.195 0.02; 2.14 | 0.7 0.811 0.06; 9.42 | 0.07 |
| Macular edema (OCT) | 14 (21.5%) | 4 (12.5%) | 2 (6.1%) | b | b | b | 0.08 |
| Epiretinal membrane formation (Funduscopy) | 7 (5.5%) | 7 (8.5%) | 4 (5.9%) | b | b | b | 0.12 |
| Epiretinal membrane formation (OCT) | 7 (11.3%) | 7 (17.5%) | 5 (14.3%) | b | b | b | 0.11 |
| Vitreous haze (yes/no) | 15 (16.3%) | 15 (18.3%) | 13 (19.1%) | 1.6 0.518 0.38; 6.97 | 1.5 0.632 0.31; 6.75 | 0.9 0.89 0.20; 4.11 | 0.06 |
| Other complications | 12 (12.8%) | 2 (2.4%) | 0 (0.0%) | b | b | b | 0.10 |
beta regression coefficient for continuously distributed variables, CI confidence interval, n number of patients with valid assessment in the reported parameter, OR Odds ratio for categorical variables, sd standard deviation
apercentages refer to the number of patients or eyes with valid assessments in the considered parameter
bnot estimable due to the low number of complications